Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells

Julia A. Sung, Katherine Sholtis, Jennifer Kirchherr, Joann D. Kuruc, Cynthia L. Gay, Jeffrey L. Nordstrom, Catherine M. Bollard, Nancie M. Archin, David M. Margolis

Department of Cellular Therapy, Children’s National Medical Center, Washington, DC 20010, United States
Departments of Medicine
McGenics, Inc., Rockville, MD 20850, United States
UNC Center for AIDS Research, University of North Carolina Chapel Hill, Chapel Hill, NC 27599, United States
Microbiology & Immunology
Department of Medicine
UNC HIV Cure Center
Microbiology & Immunology

1. Introduction

Antiretroviral therapy (ART) is highly successful at suppressing viral replication in HIV-infected individuals, yet viremia returns following the cessation of therapy due to the persistence of replication-competent human immunodeficiency virus (HIV) in a quiescent, latent reservoir (Chun et al., 1997, 2010; Finzi et al., 1999). Currently, one of the most well-developed strategies for eradication of the latent HIV reservoir hinges on inducing viral antigen expression through exposure to a latency reversing agent, allowing for detection by immune effector cells, followed by subsequent clearance of the now vulnerable infected cells by the immune response or other therapeutics (Archin and Margolis, 2014).

Inhibitors of histone deacetylases (HDACis) target the formation of a repressive chromatin environment that inhibits long terminal repeat (LTR) expression and viral production, and may be useful in eradication strategies. A significant increase in cell-associated ribonucleic acid (RNA) production following in vivo administration of HDAC inhibitors, including vorinostat (VOR), to ART-suppressed individuals has been shown in initial proof of concept studies (Archin et al., 2014; Sogaard et al., 2015; Elliott et al., 2014; Rasmussen et al., 2014; Archin et al., 2012). Additional studies have shown that VOR leads to induction of genetically diverse cell-associated RNA that is similar to the diversity found in corresponding deoxyribonucleic acid (DNA) sequences, suggesting activation of transcription from a broad representation of persistently latent HIV-1 proviruses (Barton et al., 2016).

However, measurements of cell-associated HIV RNA expression are limited in several respects. Such RNA measurements following ex vivo stimulation overestimate the frequency of latent but replication-competent virus (Eriksson et al., 2013). The majority of HIV RNA detected in such assays encode mutations or deletions that render them unable to produce infectious virions, and are therefore clinically irrelevant from the standpoint of eradication efforts (Barton et al., 2015; Bruner et al., 2016; Ho et al., 2013). Cell-associated HIV RNA is thus an imperfect surrogate for infectious virion production. Further, if immunotherapies are to be used to clear persistent infection then effective latency reversal must be defined as the presentation of viral protein or antigen by the latently infected cell in a sufficient quantity and for a sufficient length of time for cells harboring replication competent virus to be recognized and cleared. As direct measurement of
rare or low-level HIV-1 protein or peptide production following latency reversal is not achievable with currently available assays, we have developed the latency clearance assay (LCA) as an ex vivo assay to validate that this goal, the opening of a “window of vulnerability” in the persistent, latent reservoir of HIV infection, can be achieved by a selected intervention.

We have described the LCA in earlier demonstrations of the in-vitro efficacy of various immunotherapeutic approaches (Sung et al., 2015a, b). Previously we have shown that over a prolonged co-culture period of 15 days these interventions led to a reduction in the recovery of replication competent virus, we cannot completely exclude the possibility that inhibition of virus spread contributed to the antiviral effect observed. We therefore modified the LCA to include the addition of antiretrovirals and the removal of CD8 T cells from co-culture following a discrete period of time, and now unequivocally demonstrate that VOR produces a window of vulnerability within the latent HIV reservoir. We used multiple effector mechanisms that detect and clear distinct HIV antigens, including autologous CD8 T cells redirected to infected targets expressing HIV-1 Env on the cell surface via bispecific proteins, including autologous CD8 T cells redirected to infected targets used multiple effector mechanisms that detect and clear distinct HIV antigen expression from the autologous resting CD4 T cells of ART suppressed, HIV infected individuals can be detected and cleared by effectors. These approaches are now entering clinical proof-of-concept studies.

2. Materials and Methods

2.1. Participants

This study was reviewed and approved by the University of North Carolina at Chapel Hill Biomedical Institutional Review Board, and written informed consent obtained from each participant. The study was performed in accordance with the Declaration of Helsinki. Participants were drawn from cohorts of HIV-infected individuals on stable, suppressive ART with undetectable plasma viremia (<50 copies/ml) for at least 24 months.

2.2. Latency Clearance Assay (LCA)

The LCA was performed as previously described (Sung et al., 2015a, b) with the following modifications. Briefly, resting CD4 T-cells were isolated from a leukapheresis product by negative selection and expressed to VOR (335n; gift of Merck Research Laboratories) at a concentration of 5 million/ml in the presence of the antiretrovirals abacavir (4 μM) and raltegravir (1 μM). After 6 h, cells were extensively washed, and effectors added at an effector:target ratio of 1:10. Antiretrovirals were again added, and cells were co-cultured at a concentration of 5 million resting CD4 T cells/ml. After 24 h, cells were extensively washed and depleted of CD8 T cells via three serial magnetic selections (StemCell Technologies, Vancouver, BC). Remaining CD4 T cells were recounted, then plated in 16 to 48 replicate wells at 0.25 to 1 million cells/well (depending on cell availability and reservoir size) and cultured with allogeneic CD8-depleted peripheral blood mononuclear cells (PBMCs) from an HIV-negative donor to amplify any residual virus. The presence of HIV Gag p24 antigen was measured on day 15, and confirmed on day 19 for each well by ELISA (ABL, Rockville, MD). Each LCA was performed at an independent time point.

2.3. Reagents and Generation of HXTCs

HXTCs were generated as previously described (Sung et al., 2015a; Lam et al., 2015). Briefly monocytes were isolated from peripheral blood mononuclear cells (PBMCs) by plastic adherence. Dendritic cells were generated using standard cytokine cocktails of IL-4, GM-CSF, IL-1β, IL-6, and TNF-α. Non-adherent PBMCs were cryopreserved and thawed upon completion of dendritic cell generation. PBMCs were stimulated with irradiated autologous dendritic cells pulsed with Gag, Pol and Nef peptide pools in the presence of IL7, IL-15, and IL12 for an initial stimulation. Cells were then co-cultured with autologous PHA-treated blasts pulsed with Gag, Pol and Nef peptide pools in the presence of IL-15 and IL-2 for a second and IL-2 for a third round of stimulation. HIV peptide pools comprised 150, 15-mer peptides providing broad coverage of Gag p24, Pol, and Nef across clades (JPT Peptide Technologies). Irradiated K562 cells modified to overexpress the co-stimulatory molecules CD80, CD83, CD86 and 4-1BBL were used in the third stimulation. Cells were cultured in the presence of indinavir and raltegravir (Merck, Kenilworth NJ) to prevent replication of HIV.

HIV DART molecules (provided by Macrogenics) were used as previously described (Sung et al., 2015b; Sloan et al., 2015).

2.4. HIV-specific Responses

IFNγ ELISPOT assays were used to assess for the presence of HIV-specific responses in PBMCs from participants. Cryopreserved PBMCs obtained from the same leukapheresis procedure that provided PBMCs for the LCA were thawed and resting overnight for 16–24 h in RPMI with 10% FBS, 5% Pen/Strep. Cells were then harvested, recounted, and plated at 5 × 10^5 cells/well in triplicate and stimulated with peptide pools at a final concentration of 2 μg/ml for 18–20 h. For each assay, four negative control wells (no peptide, ‘Mock’) and two positive control wells (PHA at a final concentration of 10 μg/ml, Sigma-Aldrich) were included. A threshold of 4× Mock and >50 SFU/10^6 was used to determine positive responses, as previously reported by others (Goonetilleke et al., 2006, 2009).

Clade B consensus peptide pools for Gag, Nef and Pol were obtained from NIH AIDS Reagent program, Division of AIDS, NIAID, NIH.

2.5. Statistical Analysis

Statistical comparisons between groups were analyzed using the Kruskall-Wallis or Friedman nonparametric test with Dunn’s posttest correction for multiple comparisons. Fisher’s exact test was used for individual participants. p < 0.05 was considered significant.

3. Results

3.1. Participants

The 15 participants studied were all suppressed for at least 2 years, with a median duration of suppression of 5.5 years (range 2–8.5) and a wide range of latent reservoir sizes as measured by the standard quantitative viral outgrowth assay following maximal mitogenic stimulation (QVOA; median 0.76, range 0.04 to 2.30 infectious units per million resting CD4 T cells; Table 1), reflecting the spectrum of chronic HIV-1 infection.

3.2. VOR Induces MHC Presentation of HIV Peptides Detectable by CD8 T Cells

An LCA was performed for each individual participant independently, as shown in Fig. 1. Following a 6 h exposure of resting CD4 T cells to 335 nM of VOR, chosen to mimic physiologically achievable levels in vivo following both single and multiple doses of vorinostat, which maintain similar PK parameters (Archin et al., 2012; Archin et al., 2014, 2017), the frequency of cultures in which p24 was detected following VOR exposure is significantly greater than that in cultures treated with only 2 U/ml IL2 (no stimulation; Fig. 2A). As measured by a reduction in the recovery of virus from latently infected cells, VOR induced the expression of HIV to an extent sufficient to allow clearance.
by ex vivo autologous CD8+ T cells. Addition of ex vivo autologous CD8+ T cells at an effector to target ratio of 1:1 led to a significant reduction in the percentage of p24+ wells recovered, with complete ablation of viral recovery in 7 of the 9 participants studied at this ratio (Fig. 2A, p = 0.001 by Kruskal-Wallis test with Dunn’s posttest correction for multiple comparisons). This effect was dependent on CD8 T cell frequency; while there was a reduction in the percentage of p24+ wells recovered with the addition of autologous CD8 T cells at an effector:target (E:T) ratio of 1:10, this did not reach significance (Fig. 2A).

The QVOA is designed to detect the presence of absence of HIV-1 p24 within each well as a qualitative measure, rather than as a quantitative measure within each well (Archin et al., 2008). Similar to what we have seen with the traditional QVOA when PHA or VOR are used as the stimulus, in which the presence of reactivated virus in a well leads to robust viral replication and spread over the two week period that exceeds the quantifiable limits of the assay, positive wells in the LCA were also above the limit of quantification of the assay. This was true for all conditions tested; although the frequency of positive wells differed, the ability of HIV to spread within wells that were positive, as reflected by the high quantity of p24 produced, was unaffected. This is what would be expected from an effect that takes place after virus reactivation but before virus spread.

A potential approach to increasing the frequency of effective HIV-1 specific T cell immune responses is through the use of adoptive T cell therapy with ex-vivo expanded HIV-1 specific T cells (Lam et al., 2015; Sung et al., 2015a; Lam and Bollard, 2013). HIV-specific ex vivo expanded T cells (HXTCs; (Sung et al., 2015a)) are currently under clinical evaluation in ART suppressed, HIV-infected individuals (clinicaltrials.gov NCT registration number pending). HXTCs were used as effectors in the LCA, to illustrate the relevance of VOR activity in the context of a more potent antiviral response (Fig. 2B). In three participants with an incomplete reduction in virus recovery with CD8 T-cells at an E:T ratio of 1:10 (participants CP1, CP6, and CP9), the addition

### Table 1

Demographics of participants and frequency of latent infection.

| Participant | Symbol | Nadir CD4 count | Current CD4 count | Viremia suppression (years) | IUPM* | Number cells assayed with VOR/group (million) |
|-------------|--------|-----------------|-------------------|----------------------------|-------|---------------------------------------------|
| CP1         | ▲      | 508             | 960               | 3.5                        | 0.04  | 34                                          |
| CP2         | ■      | 480             | 766               | 5.5                        | 0.05  | 24                                          |
| CP3         | •      | 49              | 610               | 8                          | 0.10  | 12                                          |
| CP4         | †      | 499             | 706               | 2                          | 0.28  | 12                                          |
| CP5         | ▼      | 277             | 615               | 7.5                        | 0.37  | 24                                          |
| CP6         | ○      | N.A.            | 704               | 8.5                        | 0.37  | 8                                           |
| CP7         | ●      | 373             | 391               | 3                          | 0.38  | 10                                          |
| CP8         | ♦      | 195             | 886               | 8.5                        | 0.76  | 30                                          |
| CP9         | □      | 338             | 857               | 4                          | 0.89  | 9                                           |
| CP10        | △      | 81              | 619               | 6.5                        | 0.97  | 12                                          |
| CP11        | u/k    | 491             | 8                 | 1.05                       | 12    |
| CP12        | ▼      | 78              | 557               | 8.5                        | 1.15  | 9                                           |
| CP13        | △      | 604             | 1302              | 2                          | 1.17  | 24                                          |
| CP14        | ○      | 243             | 439               | 4.5                        | 1.67  | 12                                          |
| CP15        | □      | 526             | 850               | 2.5                        | 2.30  | 18                                          |

CP = Participant treated in chronic, progressive HIV infection.

* Infectious units per million resting CD4 cells (IUPM) determined by Quantitative Outgrowth Assay (QVOA (Lam and Bollard, 2013)).

![Fig. 1. Latency clearance assay overview.](image-url)
of HXTCs at the same E:T ratio of 1:10 led to a further reduction in virus recovery (Fig. 2B). In contrast, no reduction in virus recovery was seen with HXTCs at the same E:T ratio of 1:10 or 1:1, (B) with or without unmodified, autologous CD8 cells or ex-vivo expanded HIV specific T cells (HXTC) at an E:T ratio of 1:10, or (C) with or without effectors in the presence or absence of MHC-I blockade (C). Results are shown as % of plated wells HIV Gag p24 positive ((#positive wells x 100) / total #plated wells). *Indicates p < 0.01 by Kruskal-Wallis with Dunn's posttest correction for multiple comparisons. **Indicates p < 0.05 by Kruskal-Wallis with Dunn's posttest correction. 3.3. CD8 T Cells From all Participants Show Detectable HIV-specific Responses

Frozen PBMCs from 13 participants were available to evaluate for the presence of HIV-specific responses, as measured by IFNγ Elispot. A conservative threshold for positive responses as >50 SFU/10⁶ PBMCs and >4× the Mock control was employed, based on prior literature (Goonetilleke et al., 2009; Goonetilleke et al., 2006; Liu et al., 2013). Using this criteria, PBMCs from all 13 participants demonstrated responses to at least one of the three tested peptide pools (Gag, Nef, or Pol) (Fig. 3). Negative responses were only seen to the Nef peptide pool (in two participants); all 13 participants demonstrated a positive detectable response to the Gag and Pol peptide pools, perhaps reflecting the more conserved nature of these proteins. A range of magnitudes of positive responses were observed across participants: 95 to 942 SFU/10⁶ PBMCs to the Gag peptide pool, 59.5 to 807 SFU/10⁶ PBMCs to the Nef peptide pool, and 62.8 to 1279 SFU/10⁶ PBMCs.

3.4. VOR Induces Cell Surface Expression of Env, Detectable by DART Molecules

We also utilized HIV DART molecules (Sung et al., 2015b) to assess the LCA in the context of an alternative clearance approach. HIV DART molecules are antibody-based bispecific proteins that redirect polyclonal T cells to HIV-1 Env-expressing cells. We tested DART molecules with an HIV-specific domain that is based on the variable region of the broadly binding antibodies 7B2 (directed towards a gp41 epitope) or A32 (directed towards a CD4 induced gp120 epitope) (Acharya et al., 2014; Pincus et al., 2003). Thus, CD3+ effector cells are recruited to bind and kill HIV Env-expressing cells regardless of underlying TCR specificity. We have previously shown that HIV DART molecules are capable of redirecting T cells against autologous reservoir virus as well as against rare latent infection in resting CD4+ T cells (Sung et al., 2015b). Here, with the additional step of depletion of CD8 T cells prior to addition of allogeneic target cells, we show that HIV DART molecule-mediated redirection of effector T cells directly recognizes and clears latent infected cells expressing HIV Env in the 24-hour period following VOR exposure. Even at the E:T ratio of 1:10, the addition of HIV DART molecules to CD8+ T cells led to a significant reduction in recovery of p24+ wells (Fig. 4, p < 0.05 by Kruskal-Wallis with Dunn’s post-test correction). In comparison, CD8+ T cells alone at an E:T ratio of 1:10 were unable to significantly reduce recovery of p24+ wells in this subset of 6
participants, consistent with what was observed at this lower E:T ratio in Fig. 2, nor was the addition of a control DART molecule in which the HIV-specific arm is replaced by an irrelevant arm (Fig. 4). This indicates that a 6-hour exposure to VOR led to sufficient Env protein expression on the cell surface to allow detection by an antibody-based mechanism such as the HIV DART molecules.

As a control for the LCA, we sought to recover virus from the population of cells that were depleted by anti-CD8+, to rule out the possibility that CD8 depletion had also removed HIV-infected cells. No virus was recovered from co-culture of these cell fractions. Furthermore, no CD8+ T cells were detectable in the co-cultures by FACS analysis either immediately following depletion from co-culture, or at the conclusion of the 2 week co-culture period with allogeneic target cells (hence not shown).

4. Discussion

The latency clearance assay was designed to provide evidence that effectors could recognize and clear infected cells following exposure to a latency reversal agent. An important feature of the assay is that it is performed in an all-autologous system, using methodology (e.g. drug concentrations, exposure times) that reflects pharmacologically relevant conditions. To ensure that any reduction of virus recovery can be attributed specifically to the activity of the immune effectors under study, effectors are depleted from co-culture with infected cells prior to amplification of remaining virus by co-culture in allogeneic target cells.

Jones et al. (2016) has studied the ability of selected CD8+ T cell clones to target latent HIV infection in a primary cell model of latency. In this study, HIV-specific CD8+ cells did not recognize latently infected cells treated with VOR. However, primary cell models are variably responsive to latency reversing agents, including VOR, when compared to the responses of resting CD4+ T cells from HIV infected individuals (Spina et al., 2013; Laird et al., 2015). Additionally, the ex vivo exposure of VOR used in these experiments is approximately three times higher and longer than can be achieved in vivo, and is likely to blunt T cell function (Clutton et al., 2016).

In contrast in the LCA reported here, using an all-autologous system encompassing the use of specific participant-derived cells, we found that VOR induced the expression of HIV to an extent sufficient to allow clearance by ex vivo autologous CD8+ T cells, as measured by a reduction in the recovery of virus from authentic participant-derived latently infected cells. Unlike in this ex vivo study, vorinostat treatment in vivo has not led to a detectable reduction in the size of the latent reservoir (Archin et al., 2012, 2014; Elliott et al., 2014). This may be due to the inadequacy of a single or short term in vivo vorinostat exposure to induce antigen from a sufficient proportion of the total replication competent latent reservoir to detect reductions in current assays, complexities involving maintenance of the latent reservoir, and/or defects in the in vivo CD8 T cell response (Deng et al., 2015). The CD8 mediated clearance we observed was dependent on the frequency of CD8 T cells, consistent with our earlier published results using the unmodified LCA (Sung et al., 2015a, b) as well as findings from other groups (Shan et al., 2012; Walker-Sperling et al., 2015). This suggests that a low frequency of circulating HIV-specific effector cells may limit immune clearance following latency reversal in vivo, but that this limitation could potentially be overcome by interventions that increase the frequency of HIV-specific CD8 T cells, such as HXTC therapy, or different immunotherapeutic approaches such as DART molecules.

The LCA as employed in this study does not directly address the possible impact of vorinostat on the CD8 T cell function, as vorinostat was purposefully removed from culture prior to addition of CD8 T cells. This was purposeful, as the focus of the current work is on the ability of vorinostat to induce antigen expression, rather than evaluation of any impact on CD8 T cell function. The potential impact of vorinostat on CD8 T cell function has been recently addressed with multiple rigorous and extensive studies. We have previously shown that vorinostat doses reflecting achievable in vivo peak doses and exposures did not decrease CD8 T cell ability to inhibit HIV virus replication, or T cell proliferation, and that supraphysiologic exposures were required to produce any measurable impact on CD8 T cell function (Sung et al., 2015a), a finding consistent with other groups that have examined escalated in vitro exposures to vorinostat (Jones et al., 2016). Clutton et al. found that exposures of vorinostat that reflect what is achievable following single and multiple doses (Archin et al., 2014), did not decrease CD8 T cell function as measured by cytokine release and proliferation (Clutton et al., 2016), and that a single dose of in vivo vorinostat had no significant impact on CD8 T cell function either. These findings have been replicated in studies examining multiple in vivo doses of vorinostat (Elliott et al., 2014; Archin et al., 2017). Looking forward, the LCA can, with minor modification, be used to evaluate a new latency reversal agents impact on the CD8 T cell function against rare, latently infected resting CD4 T cells.

The LCA is limited by the rare nature of latent infection in ART suppressed individuals, leading to a large number of cells needing to be assayed in each condition to obtain detectable positive signals. This also limits the number of replicates and statistical robustness of the data. The assay does require a substantial number of resting CD4 T cells and is labor and time intensive. The LCA is thus not an appropriate screening tool for LRAs, but rather is best reserved for evaluating the most promising LRAs prior to or in parallel to clinical investigation.

It is possible that assaying a higher number of cells could have led to a higher number of wells plated in which virus was recovered, as the sensitivity of the assay is limited by the number of cells available. Given available cells, 8−34 million resting CD4 T cells were assayed per condition (Table 1), which is fewer than typically assayed to quantitate the frequency of latent infection QVOA (Archin et al., 2008; Crooks et al., 2015). However, the reduction of viral recovery is uniformly seen in the presence of active effectors. The use of cells directly from ART-suppressed individuals, and the readout of replication competent virus, increases the relevance of the data generated. As strategies are developed for clinical testing, assays such as the one presented herein will be useful in assessing and confirming the ability of LRAs to induce levels...
of antigen production that might be relevant for viral clearance strategies. We used multiple tools and controls to interrogate the ability of VOR to induce detectable antigen expression, with consistent results across these approaches and conditions.

In summary, we have demonstrated that VOR is capable of inducing HIV MHC:peptide as well as Env antigen expression on the cell surface of latently infected, resting CD4 cells from ART suppressed individuals at levels sufficient for clearance by a variety of effector mechanisms. The same methods can be adapted to further understand the kinetics of latency clearance, modeling exposures to an array of LRAs (or combination approaches) and effector mechanisms. Such efforts will be essential for the rational design of optimal combination latency reversal and clearance strategies. Our ongoing clinical trials will attempt to validate the LRA and clearance activities measured in the ex vivo LCA. Latency clearance activity observed in this study suggests that HDAC inhibitors such as VOR may prove useful when used in appropriate combination with immune clearance strategies. Further, these findings underscore the potential value of evaluating latency reversing agents within the context of viral clearance ex vivo, prior to ultimate in vivo testing.

Conflict of Interest Statement

The authors report no conflicts of interest.

Funding

This work was supported by National Institutes of Health grant numbers U19-AI096113 and UM1AI126619 to DMM and the Collaboratory of AIDS Researchers for Eradication, RO1 HL132791 to DMM and CMB, KL2 TR001109 to JMS, P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center for the UNC Flow Cytometry Core Facility, and the UNC CFAR P30 AI054100.

Author Contributions

JS wrote the manuscript and designed, supervised and performed experiments. DM, NA, JN, and CB edited the manuscript and provided input into and supervision for experiment design. KS and JK performed experiments and edited the manuscript. JDC and CG coordinated clinical input into and supervision for experiment design. KS and JK performed experiments and edited the manuscript. JDK and CG coordinated clinical input into and supervision for experiment design. KS and JK performed experiments and edited the manuscript.

Acknowledgments

We thank CM Rooney and the PACT through Baylor School of Medicine for their generous provision of HXTCs. We thank M Hudgens who provided statistical input. Importantly, we thank the HIV-positive participants involved in this project, JMS, NMA, and DMM designed and conducted experiments. CB provided advice on use of and experimental design involving HXTCs and JLN provided DART molecules and advice for their experimental use. JK and KS provided technical support and JDC and CLG provided clinical study management. JS authored the manuscript and all coauthors edited the manuscript.

References

Acharya, P., Tolbert, W.D., Gohain, N., Wu, X., Yu, L., Liu, T., Huang, W., Huang, C.C., Kwon, Y.D., Louder, R.K., Tsang, T.S., McElwan, J.S., Pancera, M., Yang, Z., Zhang, B., Flinko, R., Fouilleur Jr., J.S., Sajadi, M.M., Kamin-lewis, R., Robinson, J.E., Martin, L., Kwong, P.D., Guan, Y., Devico, A.L., Lewis, K.G., Pazgier, M., 2014. Structural definition of an antibody-dependent cytotoxicity response implicated in reduced risk for HIV-1 infection. J. Virol. 88, 12895–12906.

Archin, N.M., Margolis, D.M., 2014. Emerging strategies to deplete the HIV reservoir. Curr. Opin. Infect. Dis. 27, 29–35.

Archin, N.M., Eron, J.J., Palmer, S., Hartmann-Duff, A., Martinson, J.A., Wiegand, A., Bandarenko, N., Schmitz, J.L., Bosch, R.J., Landay, A.L., Coffin, J.M., Margolis, D.M., 2008. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22, 1131–1135.

Archin, N.M., Liberty, A.L., Kashuba, A.D., Choudhary, S.K., Kuruc, J.D., Crooks, A.M., Parker, D.C., Anderson, E.M., Kearney, M.F., Strain, M.C., Richman, D.D., Hudgens, M.G., Bosch, R.J., Coffin, J.M., Eron, J.J., Hazuda, D.J., Margolis, D.M., 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 483–485.

Archin, N.M., Bateson, R., Tripathy, M.K., Crooks, A.M., Yang, K.H., Dahil, D.P., Karel, D., Anderson, E.M., Coffin, J.M., Strain, M.C., Richman, D.D., Robertson, K.R., Kashuba, A.D., Bosch, R.J., Hazuda, D.J., Kuruc, J.D., Eron, J.J., Margolis, D.M., 2014. HIV-1 expression with- out plasma proviruses in CD4+ T cells is associated with increased viral reservoirs. Proc. Natl. Acad. Sci. U.S.A. 111, 13193–13197.

Barton, K., Deeks, S.G., Fauci, A.S., 2013. The HIV reservoir: implications for eradication. J. Clin. Invest. http://dx.doi.org/10.1172/JCI75394 [Epub ahead of print].

Barton, K., Hiebner, B., Winnickelmann, A., Rassmann, T.A., Shao, W., Byth, K., Lanfer, K., Solomon, A., Mcmahon, J., Harrington, S., Buzon, M., Lichterfeld, M., Denton, P.W., Olesen, R., Ostergard, I., Tolstrup, M., Lewin, S.R., Sogarda, O.S., Palmer, S., 2016. Broad activation of latent HIV-1 by a novel combination of induction agents. Nat. Commun. 7, 12717.

Brunner, K.M., Murray, A.J., Pollack, R.A., Soliman, M.G., Laskey, S.B., Capoferri, A.A., Lai, J., Strain, M.C., Lada, S.M., Hoh, R., Ho, Y.C., Richman, D.D., Seeks, G.G., Siliciano, J.D., 2016. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat. Med. 22, 1043–1049.

Chun, T.W., Stuyver, L., Mizell, S.B., Ehler, L.A., Mican, J.A., Baseler, M., Lloyd, A.L., Nowak, M.A., Fauci, A.S., 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 94, 13193–13197.

Conflit de Intérêt Énoncé

Les auteurs déclarent ne pas avoir d’intérêts de conflit.

Fonds

Ce travail a été soutenu par le National Institutes of Health grant numbers U19-AI096113 et UM1AI126619 à DMM et le Collaboratory of AIDS Researchers for Eradication, RO1 HL132791 à DMM et CMB, KL2 TR001109 à JMS, P30 CA016086 Cancer Center Core Support Grant à l’UNC Lineberger Comprehensive Cancer Center pour l’UNC Flow Cytometry Core Facility, et l’UNC CFAR P30 AI054100.

Auteurs Contribution

JS a écrit le manuscrit et a dirigé, supervisé et effectué les expériences. DM, NA, JN et CB ont contribué à l’écriture du manuscrit et ont participé à la supervision pour la conception des expériences. KS et JK ont effectué les expériences et corrigé le manuscrit. JDC et CG ont coordonné la participation clinique.

Reconnaissances

Nous remercions CM Rooney et le PACT à travers la School of Medicine pour leur généreuse fourniture de HXTCs. Nous remercions M Hudgens qui a fourni une aide statistique. Importamment, nous remercions les participants vivant avec le virus HIV positifs qui ont participé à ce projet, JMS, NMA et DMM ont conçu et dirigé les expériences. CB a fourni des conseils sur l’utilisation et la conception expérimentale impliquant HXTCs et JLN a fourni des molécules DART et des conseils sur leur utilisation expérimentale. JK et KS ont fourni le soutien technique et JDC et CLG ont fourni l’aide clinique et la gestion du manuscrit. JS a écrit le manuscrit et tous les auteurs ont corrigé le manuscrit.
Liu, M.K., Hawkins, N., Ritchie, A.J., Ganusov, V.V., Whaley, V., Brackenridge, S., Li, H., Pavlick, J.W., Cai, F., Rose-Abrahams, M., Treurnicht, F., Pater, P., Riou, C., Gray, C., Ferrari, G., Tanner, R., Ping, L.H., Anderson, J.A., Swanson, R., B., C., Cohen, M., Karim, S.S., Haynes, B., Borrow, P., Perelson, A.S., Shaw, G.M., Hahn, B.H., Williamson, C., Corber, B.T., Gao, F., Self, S., McMichael, A., Goonetilleke, N., 2013. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J. Clin. Invest. 123, 380–393.

Pincus, S.H., Fang, H., Wilkinson, R.A., Marcotte, T.K., Robinson, J.E., Olson, W.C., 2003. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. J. Immunol. 170, 2236–2241.

Rasmussen, T.A., Tolstrup, M., Brinkmann, C.R., Olesen, R., Erikstrup, C., Solomon, A., Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., Lichterfeld, M., Lewin, S.R., Ostergaard, L., Sogaard, O.S., 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–21.

Shan, L., Deng, K., Shroff, N.S., Durand, C.M., Rabi, S.A., Yang, H.C., Zhang, H., Margolick, J.B., Blankson, J.N., Siliciano, R.F., 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491–501.

Sloan, D.D., Lam, C.Y., Irinkil, A., Liu, L., Tsai, A., Pace, C.S., Kaur, J., Mury, J.P., Balakrishnan, M., Moore, P.A., Johnson, S., Nordstrom, J.L., Cihlar, T., Koenig, S., 2015. Targeting HIV reservoir in infected CD4 T cells by dual-affinity re-targeting molecules (DARTs) that bind HIV envelope and recruit cytotoxic T cells. PLoS Pathog. 11, e1005233.

Sogaard, O.S., Graversen, M.E., Leth, S., Olesen, R., Brinkmann, C.R., Nissen, S.K., Kjaer, A.S., Schleimann, M.H., Denton, P.W., Hey-Cunningham, W.J., Koelsch, K.K., Pantaleo, G., Krogsgaard, K., Sommerfelt, M., Fromentin, R., Chomont, N., Rasmussen, T.A., Ostergaard, L., Tolstrup, M., 2015. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142.

Spina, C.A., Anderson, J., Archin, N.M., Bosque, A., Chan, J., Famiglietti, M., Greene, W.C., Kashuba, A., Lewin, S.R., Margolis, D.M., Mau, M., Ruelas, D., Saleh, S., Shirakawa, K., Siliciano, R.F., Singhania, A., Soto, P.C., Terry, V.H., Verdin, E., Woelfk, C., Wooden, S., Xing, S., Planelles, V., 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9, e1003834.

Sung, J.A., Lam, S., Garrido, C., Archin, N., Rooney, C.M., Bollard, C.M., Margolits, D.M., 2015a. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J. Infect. Dis. 212, 258–263.

Sung, J.A., Pickeral, J., Liu, L., Stanfield-Oakley, S.A., Lam, C.Y., Garrido, C., Pollara, J., Labranche, C., Bonsignori, M., Moody, M.A., Yang, Y., Parks, R., Archin, N., Allard, B., Kirchherr, J., Kuruc, J.D., Gay, C.L., Cohen, M.S., Ochsenbauer, C., Soderberg, K., Liu, H.X., Montefiori, D., Moore, P., Johnson, S., Koenig, S., Lewin, B.F., Nordstrom, J.L., Margolis, D.M., Ferrari, G., 2015b. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125, 4077–4090.

Walker-Sperling, V.E., Cohen, V.J., Tarwater, P.M., Blankson, J.N., 2015. Reactivation kinetics of HIV-1 and susceptibility of reactivated latently infected CD4+ T cells to HIV-1-specific CD8+ T cells. J. Virol. 89, 9631–9638.